Innovent Biologics Inc Cash Flow Reinvestment Rate
Innovent Biologics Inc cash flow reinvestment rate. Innovent Biologics Inc (6IB) has a Cash Flow Reinvestment Rate of 9.11x as of December 2020, reinvesting €1.99 Billion (capex €211.14 Million plus investments €-1.78 Billion) from operating cash flow of €217.96 Million. Explore 6IB operating cash flow to total debt to assess how comfortably operating cash covers total debt obligations.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Cash Flow Reinvestment Rate of Innovent Biologics Inc (2023–2025)
Cash flow reinvestment rate of Innovent Biologics Inc from 2023 to 2025. Historical reinvestment intensity for Innovent Biologics Inc across 3 annual periods. Explore Innovent Biologics Inc capital spending ratio to see what proportion of operating cash flow is directed to capital expenditures.
Innovent Biologics Inc Cash Flow Reinvestment Rate by Year (2023–2025)
Innovent Biologics Inc cash flow reinvestment rate by year from 2023 to 2025. Year-by-year capital reinvestment analysis for Innovent Biologics Inc. For the full cash flow conversion analysis, see Innovent Biologics Inc cash conversion from operations.
| Year | Reinvestment Rate | Total Reinvested (EUR) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.71x | €7.06 Billion | €10.00 Billion | €683.27 Million | ▼ -48.8% |
| 2024 | 1.38x | €1.78 Billion | €1.29 Billion | €1.71 Billion | ▼ -86.9% |
| 2023 | 10.51x | €1.55 Billion | €147.81 Million | €1.38 Billion | — |